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Prevalence and management of pain in Italian patients with
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M Di Maio, C Gridelli*, C Gallo, L Manzione, L Brancaccio, S Barbera, SF Robbiati, GP Ianniello, F Ferrau `,
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F Perrone
Pain is a highly distressing symptom for patients with advanced cancer. WHO analgesic ladder is widely accepted as a guideline for its
treatment. Our aim was to describe pain prevalence among patients diagnosed with advanced non-small-cell lung cancer (NSCLC),
impact of pain on quality of life (QoL) and adequacy of pain management. Data of 1021 Italian patients enrolled in three randomised
trials of chemotherapy for NSCLC were pooled. QoL was assessed by EORTC QLQ-C30 and LC-13. Analgesic consumption during
the 3 weeks following QoL assessment was recorded. Adequacy of pain management was evaluated by the Pain Management Index
(PMI). Some pain was reported by 74% of patients (42% mild, 24% moderate and 7% severe); 50% stated pain was affecting daily
activities (30% a little, 16% quite a bit, 3% very much). Bone metastases strongly affected presence of pain. Mean global QoL linearly
decreased from 64.9 to 36.4 from patients without pain to those with severe pain (Po0.001). According to PMI, 616 out of 752
patients reporting pain (82%) received inadequate analgesic treatment. Bone metastases were associated with improved adequacy
and worst pain with reduced adequacy at multivariate analysis. In conclusion, pain is common in patients with advanced NSCLC,
significantly affects QoL, and is frequently undertreated. We recommend that: (i) pain self-assessment should be part of oncological
clinical practice; (ii) pain control should be a primary goal in clinical practice and in clinical trials; (iii) physicians should receive more
training in pain management; (iv) analgesic treatment deserves greater attention in protocols of anticancer treatment.
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Pain is a common symptom experienced by cancer patients
(Cleary, 2000). Pain prevalence and severity do increase with the
extension of disease: about half of all cancer patients report some
degree of pain, but this percentage rises to 74% in the advanced
and terminal stages (Bonica, 1990). Among cancer patients with
advanced disease, pain is moderate to severe in 40–50% and very
severe or excruciating in 25–30% (Daut and Cleeland, 1982).
Lung cancer is the first cause of cancer death (Parkin, 2001) and
it is mostly diagnosed at an advanced stage. Lung cancer-related
pain depends on the location of the primary tumour, its loco-
regional extension and metastatic spread. Pain may be secondary to
peripheral growth of the primary tumour (e.g. pleural or chest wall
involvement) or to nerve involvement (pain in the arm or in the
shoulder, or the classic Pancoast syndrome). Sometimes a visceral
pain can occur, unrelated to the invasion of local structures,
presenting as a nonspecific and vague chest pain referred to the
ipsilateral hemithorax (Ginsberg et al, 1997). Pain can finally be
related to metastatic disease, for example, bone metastases, that
occur in approximately one-third of patients (Coleman, 1997), or
brain metastases, that can cause headache and symptoms related to
intracranial hypertension. Moreover, pain may be unrelated to
cancer itself, and rather depend from coexisting diseases (e.g.
osteoarthritis), particularly common in elderly patients.
Disease symptoms can have a great impact on functional status
and quality of life (QoL). Pain is without any doubt among the
most distressing symptoms experienced by cancer patients. A
recent study of patients with chronic nonmalignant pain reported
significant correlations between severity of pain and QoL (Becker
et al, 1997). Pain, psychological control and spiritual uncertainty
have been indicated as the best predictors of QoL scores in cancer
patients (Ferrell et al, 1995). In 216 patients with metastatic cancer,
Wang et al (1999) found that increasing severity of pain was
associated with worsening health-related functioning.
Despite the existence of published and well-known guidelines
for cancer pain management recommended by the World Health
Organization (World Health Organization, 1996), undertreatment
of pain remains an outstanding problem for the correct treatment
of cancer patients, as already emerged from several studies
conducted in different countries (Cleeland et al, 1994; Larue et al,
1995; Zenz et al, 1995; Wang et al, 1999). This is disappointing
because, with a correct use of WHO analgesic ladder, up to 88% of
patients is reported to obtain satisfactory relief from pain
(Ventafridda et al, 1987; Zech et al, 1995). It is recommended
that treatment should start at the step of the analgesic ladder
appropriate for the severity of pain, and all patients with
moderate-to-severe cancer pain, regardless of aetiology, should
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lreceive a trial of opioid analgesia (Jacox et al, 1994). However, very
frequently this does not happen.
Objective of this study is to describe the prevalence of pain
among patients affected by advanced non-small-cell lung cancer
(NSCLC), the impact of pain on health-related QoL and the
adequacy of pharmacologic management of pain.
PATIENTS AND METHODS
Patients
All patients with advanced NSCLC enrolled in three multicentre
randomised clinical trials of first-line chemotherapy performed by
our cooperative group between 1996 and 2001 (The ELVIS Group,
1999; Gridelli et al, 2003a,b) were eligible for this study. All three
studies were approved by Ethical Committees and all patients gave
written informed consent. They had stage IV or IIIB (with
supraclavicular metastatic nodes or malignant pleural effusion)
disease and a baseline performance status not worse than 2,
according to ECOG scale (Oken et al, 1982). Patients with clinically
overt brain metastases were not eligible.
In the ELVIS study (Elderly Lung cancer Vinorelbine Italian
Study) vinorelbine was compared with supportive care alone in
patients X70 years (The ELVIS Group, 1999). Vinorelbine was
given 30mgm
 2 on days 1 and 8 every 3 weeks, for six cycles. The
primary end point of the trial was health-related QoL. Recruitment
started in April 1996 and overall 191 patients were randomised
until November 1997.
The MILES study (Multicentre Italian Lung cancer in the Elderly
Study) was conducted in the same age group of the ELVIS trial,
and compared the combination of vinorelbine and gemcitabine vs
the two single drugs (Gridelli et al, 2003a). Patients were randomly
assigned vinorelbine alone (30mgm
 2), gemcitabine alone
(1200mgm
 2), or combination of vinorelbine (25mgm
 2) plus
gemcitabine (1000mgm
 2). All treatments were delivered on days
1 and 8 every 3 weeks for six cycles. The primary end point was
overall survival; 707 patients were randomised between December
1997 and November 2000.
The GEMVIN study was conducted with adult (o70 years)
patients, randomly assigned either combination of vinorelbine
(25mgm
 2, days 1 and 8) plus gemcitabine (1000mgm
 2, days 1
and 8) or cisplatin-based chemotherapy: cisplatin (80mgm
 2, day
1) plus either gemcitabine (1200mgm
 2, days 1 and 8) or
vinorelbine (30mgm
 2, days 1 and 8) for six cycles of 21 days
(Gridelli et al, 2003b). The study aimed to assess whether the
combination of gemcitabine and vinorelbine improved QoL,
without shortening survival, compared to standard platinum-
containing regimens. Accrual started in Italy in October 1998, and
in Canada in May 1999. Overall, 503 patients (414 in Italy) were
randomised between October 1998 and March 2001. In this
secondary analysis, only Italian patients are considered.
Assessment of pain and QoL
The European Organization for Research and Treatment of Cancer
(EORTC) core questionnaire (QLQ-C30) and the lung-cancer-
specific module (QLQ-LC13), evaluating specific symptoms of lung
cancer, were used to evaluate QoL (Aaronson et al, 1993; Bergman
et al, 1994). Both questionnaires are designed to be completed by
the patient.
Pain is assessed by two items in the QLQ-C30: item 9 (During
the past week have you had pain?) and item 19 (During the past
week did pain interfere with your daily activities?). Further three
items addressing pain during the last week are present in the QLQ-
LC13: item 10 (Have you had pain in your chest?), item 11 (Have
you had pain in your arm or shoulder?) and item 12 (Have you had
pain in other parts of your body). All these items are scored in four
categories (Not at all/A little/Quite a bit/Very much): in this paper,
these categories have been renamed as no pain, mild, moderate
and severe pain, respectively. In the present analysis, in order to
describe the relationship between pain and QoL and to evaluate the
adequacy of analgesic treatment, the worst pain reported by each
patient at baseline assessment (merging item 9 of QLQ-C30 and
items 10, 11, 12 of QLQ-LC13) has been considered.
Global QoL is assessed by item 29 (How would you rate your
overall physical condition during the past week?) and item 30 (How
would you rate your overall QoL during the past week?) of QLQ-
C30. Both items are scored 1 (Very poor)t o7( Excellent).
Functional scales assessed by the QLQ-C30 are physical function-
ing (items 1–5), role functioning (items 6 and 7), emotional
functioning (item 21–24), cognitive functioning (items 20 and 25)
and social functioning (items 26 and 27). According to the Manual
of the EORTC QoL Study Group (Fayers et al, 1999), global QoL
and functioning scales were rescaled by calculating the mean raw
scores of single items and transforming them linearly so that each
ranged from 0 to 100. For Global QoL and functioning scales, the
higher the value the better the level of function.
Protocol requirements and data collection on analgesic
treatment
In all the three trials, study protocols recommended that analgesic
treatment should have been prescribed on an around-the-clock
basis and not only ‘as needed’. World Health Organization three-
step analgesic ladder (World Health Organization, 1996) was
recommended. This strategy consists of three steps of increasing
analgesic potency: (1) a nonopioid (e.g. a nonsteroidal anti-
inflammatory drug or acetaminophen); (2) a weak opioid for mild
to moderate pain (e.g. tramadol or codeine); and (3) a strong
opioid for moderate-to-severe pain (e.g. morphine or fentanyl).
The three trials had the same Case Report Form for data
collection on supportive drugs. Data were collected from the
starting date of chemotherapy until interruption, for up to seven
drugs in each cycle of chemotherapy (corresponding to a theoretic
21-days period), with the daily dose and the number of days of
assumption recorded. The CRF had to be filled in by the
Investigator after each cycle, so the data refer to the actual
assumption by the patient, and not to the intended prescription.
Analgesic drugs assumed by patients have been coded according
to the Anatomical Therapeutic Chemical (ATC) classification
system (World Health Organization Collaborating Centre for Drug
Statistics Methodology, 2002; Di Maio et al, 2003) and according to
the WHO three-step analgesic ladder as for the analgesic potency.
Pain management index
In the present analysis, only analgesic drugs assumed during the 3
weeks following baseline assessment (i.e. the time period
corresponding to the first cycle of chemotherapy) were considered.
Analysis has been limited to 21 days in order to evaluate the
adequacy of analgesic treatment in relation to pain assessed at
baseline. According to the WHO guidelines, management of cancer
pain is considered adequate when there is consistency between the
level of pain reported by the patient and the potency of the
analgesic drug prescribed.
The Pain Management Index (PMI) (Cleeland et al, 1994)
compares within each patient the most potent analgesic prescribed
with the self-reported level of pain. As in the original paper, for
each patient we derived the highest level of analgesic used, out of
four possible levels: no analgesic drug (score 0); a nonopioid, for
example, a nonsteroidal anti-inflammatory drug or acetaminophen
(score 1); a weak opioid, for example, tramadol or codeine (score
2); a strong opioid, for example, morphine (score 3). We then
defined the patient’s level of pain as the worst pain score reported
in the baseline QoL questionnaires (item 9 of QLQ C30 and items
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l10, 11, 12 of QLQ LC13). The absence of pain was scored as 0, mild
pain as 1, moderate pain as 2 and severe pain as 3.
The PMI, computed by subtracting the pain level from the
analgesic level, ranges from  3 (a patient suffering severe pain but
not receiving analgesic drugs) to þ3 (a patient receiving a strong
opioid and reporting no pain). Negative scores are considered to
indicate inadequate analgesic treatment, and scores of 0 or higher
are considered to be a conservative indicator of acceptable
treatment.
Statistical methods
Patients studied had been enrolled in three different randomised
clinical trials (RCT), two addressed to older people (X70 years)
and one limited to adult patients (o70 years). To counteract
differences in pain assessment and baseline covariates that could
eventually occur among the three trials, all analyses were adjusted
by stratifying by RCT. A preliminary comparison of baseline
covariates was assessed by w
2 test.
Stratified Wilcoxon rank-sum test was used to investigate
relationship between the worst pain reported and baseline
characteristics (StatXact
r, CYTEL software Corp. 2002); differ-
ences of worst reported pain among RCTs were assessed by
Kruskal–Wallis nonparametric ANOVA.
Impact of pain on QoL scales was evaluated by Jonckheere–
Terpstra test because of the ordered nature of both variables.
Association between adequacy of pain management and baseline
covariates was assessed by Mantel–Haenszel test stratified by RCT.
Factors affecting adequate pain management were finally evaluated
by a stratified logistic regression model; the explanatory variables
of the model, defined ‘a priori’, were gender, Performance Status (2
vs 0–1), stage (IV vs IIIB), bone metastases (yes vs no) and worst
pain as a continuous variable. In this model, age could not be
evaluated because it was completely confounded by stratification.
To investigate the role of age a further logistic model not stratified
by RCT was fitted, where age (X70 vs o70) was added to all the
previous covariates.
RESULTS
Overall, 1312 patients had been enrolled in the three studies. Of
these, 291 patients (22.2%) were excluded from this analysis: 164
patients (12.5%) for missing baseline QoL questionnaire, 70 (5.3%)
for missing data about supportive drugs and 57 (4.3%) for missing
both sets of information. Thus, a database of 1021 cases was used
for all the analyses (Figure 1).
Baseline characteristics are described in Table 1. Overall median
age was 72 years (range 35–86) and was strongly affected by 696
patients (68%) older than 70 enrolled in the ELVIS and MILES
trials. Most of the patients were males (83%), had metastatic
disease (72%, with bone metastases in 22%) and a good
Performance Status (0 or 1 in 83%). Limited differences were
observed among trials, but for bone metastases, more frequent in
adult subjects.
Prevalence of pain
Overall, pain was reported by 752 patients (74%, 95% CI 71–77%);
it was mild in 42%, moderate in 24% and severe in 7% (Table 2).
Chest pain was reported by 34% of patients and was moderate or
severe in 8%; pain in arm or shoulder was reported by 44% and
scored moderate or severe in 15%. Table 3 shows the relationship
among worst pain and baseline characteristics of the patients:
moderate/severe pain was more frequent in patients younger than
70 (39 vs 27%), in patients with worse performance status (45 vs
28%), in patients with metastatic disease (35 vs 22%) and in those
with bone metastases (53 vs 25%). No significant association was
evident between pain and gender.
Impact of pain on QoL
As shown in Table, 507 patients (50%) stated that their pain was
affecting daily activities (a little in 30%, quite a bit in 16% and very
much in 3%). Relationship among baseline pain and functional
scales of health-related QoL are detailed in Table 4. All QoL scales
were strongly affected by pain. Mean global QoL score linearly
decreased from 64.9 to 36.4 from patients with no pain to those
with severe pain (Po0.001). Mean scores of the functioning scales
(physical, role, emotional, cognitive and social) also linearly
decreased with increasing pain severity.
Adequacy of analgesic treatment
Analgesic medications assumed by the patients during the first 3
weeks following the baseline assessment are reported in Table 5
ELVIS study:
191 patients
MILES study:
707 patients
GEMVIN study
(Italian patients):
414 patients
Overall:
1312 patients
Remaining for analysis:
1021 patients
Excluded: 291 patients
Missing baseline QoL only: 164 patients
Missing supportive care only: 70 patients
Missing both: 57 patients
Figure 1 Flow-chart of the study.
Table 1 Baseline characteristics of the 1021 patients analysed by clinical
trial
Trial
ELVIS MILES GEMVIN P
a
Number of patients 135 (13%) 561 (55%) 325 (32%)
Age, years n.a.
Median 74 74 62
Range (69
b – 85) (63
b – 85) (35 – 72
c)
Gender 0.43
Male 117 (87%) 462 (82%) 266 (82%)
Female 18 (13 %) 99 (18%) 59 (18%)
Performance status 0.03
0–1 103 (76%) 461 (82%) 281 (86%)
2 32 (24%) 100 (18%) 44 (14%)
Stage 0.01
IIIB 40 (30%) 176 (31%) 72 (22%)
IV 95 (70%) 385 (69%) 253 (78%)
Bone metastases o0.001
Absent 116 (86%) 449 (80%) 231 (71%)
Present 19 (14%) 112 (20%) 94 (29%)
aw
2 test; n.a. ¼ not applicable because trials were different by design (see text).
bSeven patients (one ELVIS, six MILES) randomised although o70 years.
cTwo
patients randomised although 470 years.
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l(grouped as ATC categories) and Table 6 (grouped as WHO three-
step ladder). Despite 74% of the patients referred some pain at
baseline, only 25% assumed analgesics. Notably, no analgesic
treatment was assumed by 79% of patients with mild pain, 53%
of those with moderate pain and 50% of those suffering from
severe pain.
Table 2 Pain reported by the 1021 patients at the baseline QoL assessment
Number of patients (%)
No answer Not at all A little Quite a bit Very much
EORTC QLQ C30:
During the past week:
(a) Have you had pain? 11 (1) 392 (38) 370 (36) 206 (20) 42 (4)
(b) Did pain interfere with your daily activities? 7 (1) 507 (50) 307 (30) 166 (16) 34 (3)
EORTC QLQ LC13:
(c) Have you had pain in your chest? 10 (1) 664 (65) 267 (26) 72 (7) 8 (1)
(d) Have you had pain in your arm or shoulder? 8 (1) 563 (55) 303 (30) 119 (12) 28 (3)
(e) Have you had pain in other parts of your body? 14 (1) 640 (63) 246 (24) 97 (9) 24 (2)
Worst pain reported (a/c/d/e) — 269 (26) 433 (42) 245 (24) 74 (7)
Table 3 Relationship between worst pain and main baseline characteristics (n¼1021)
Number of patients (%)
Not at all A little Quite a bit Very much
269 (26) 433 (42) 245 (24) 74 (7)
Clinical trial o0.001
a
ELVIS 26 (19) 67 (50) 35 (26) 7 (5)
MILES 171 (30) 238 (42) 123 (22) 29 (5)
GEMVIN 72 (22) 128 (39) 87 (27) 38 (12)
Age o0.001
a
o70 years 73 (22) 129 (39) 90 (27) 38 (12)
X70 years 196 (28) 304 (44) 155 (22) 36 (5)
Gender 0.69
b
Male 221 (26) 363 (43) 205 (24) 56 (7)
Female 48 (27) 70 (40) 40 (23) 18 (10)
Performance status o0.001
b
0–1 241 (29) 364 (43) 187 (22) 53 (6)
2 28 (16) 69 (39) 58 (33) 21 (12)
Stage o0.001
b
IIIB 89 (31) 136 (47) 50 (17) 13 (5)
IV 180 (25) 297 (41) 195 (27) 61 (8)
Bone metastases o0.001
b
Absent 249 (31) 347 (44) 164 (21) 36 (4)
Present 20 (9) 86 (38) 81 (36) 38 (17)
aKruskal–Wallis test.
bWilcoxon rank-sum test stratified by clinical trial.
Table 4 Mean scores of baseline global health status and functioning scales by worst pain categories
Worst pain reported
Not at all A little Quite a bit Very much P
a
Global health status 64.9 56.9 45.4 36.4 o0.001
Physical functioning 88.3 82.4 74.2 68.2 o0.001
Role functioning 79.4 71.3 58.4 54.7 o0.001
Emotional functioning 78.4 70.7 62.3 53.2 o0.001
Cognitive functioning 90.9 85.9 78.2 77.0 o0.001
Social functioning 85.2 81.4 72.7 69.8 o0.001
aJonckheere–Terpstra test.
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lDrugs falling in the first step of the WHO analgesic ladder were
the most frequently used: 184 out of 256 patients receiving
analgesics (72%) and 169 out of 752 patients reporting pain (22%).
Patients with moderate or severe pain received an opioid in 18% of
cases (a weak opioid in 8% and a strong opioid in 9%). Strong
opioids, mostly orally administered slow-release morphine (fast-
release preparations were not widespread in Italy when the
patients analysed in this study were treated), were assumed by
4.4% of patients reporting pain (33 out of 752), in particular by 1, 8
and 12% of patients reporting mild, moderate and severe pain,
respectively.
In all, 82% of patients (616 out of 752 with any pain) had
negative scores of the Pain Management Index, indicating
inadequate analgesia (Table 6). The inadequacy rate tended to
increase with increasing pain severity: 79, 84 and 88% among
patients reporting mild, moderate and severe pain, respectively,
possibly as effect of more stringent criteria for adequacy with
increasing pain severity. Relationship between adequacy of pain
management during the first 3 weeks and main baseline
characteristics of the patients are detailed in Table 7. A higher
percentage of adequately treated patients was observed among
subjects older than 70 as compared to the younger ones (20 vs
14%, P¼0.02). Adequate pain treatment was more frequent in
patients with bone metastases than in those without (28 vs 14%,
Po0.001). No significant association with adequacy of pain
treatment was evident for gender, performance status and stage
of disease. At binary logistic regression, stratified by clinical trial,
the presence of bone metastases (OR 2.7, 95% CI 1.7–4.2,
Po0.0001) and worst reported pain (OR 0.6, 95% CI 0.4–0.8,
P¼0.003) were independent predictors of the adequacy of the
analgesic treatment (Table 8). When the unstratified logistic model
was fitted with age added as explanatory variable, older subjects
were found to be slightly associated with more adequate analgesic
therapy (OR 0.6, 95% CI 0.4–1.0, P¼0.05).
DISCUSSION
This study provides a description of the occurrence and the
severity of pain in a large series of patients with advanced NSCLC.
In addition, it provides two major findings, that is, a close
relationship between pain and QoL indicators and a clear evidence
of inadequate analgesic treatment in a large proportion of the
patients.
Knowledge of the prevalence of pain at diagnosis in patients
affected with advanced cancers, for whom palliation is frequently
the primary goal of treatment, may help planning organisation of
therapeutic units and strategy of clinical research could be better
Table 5 Analgesic drugs assumed by the 1021 patients during the first 3
weeks
ATC categories
n1 (%) of
patients
M01A anti-inflammatory products, nonsteroids 140 (14%)
M01AB acetic acid derivatives (e.g.diclofenac, ketorolac) 107 (10%)
M01AC oxicam (e.g. piroxicam) 4 (o1%)
M01AE propionic acid derivatives (e.g. ibuprofen, naproxen) 15 (1%)
M01AX other anti-inflammatory, nonsteroids (e.g. nimesulide) 18 (2%)
N02 analgesics 167 (16%)
N02A opioids 72 (7%)
N02AA morphine 26 (3%)
N02AB fentanyl 7 (1%)
N02AC dextropropoxyphene 1 (o1%)
N02AE buprenorphine 7 (1%)
N02AX tramadol 32 (3%)
N02B other analgesics and antipyretics 97 (9%)
N02BA salicylic acid and derivatives 3 (o1%)
N02BE anilides (e.g. acetaminophen) 23 (2%)
N02BE in association with opioids (codeine+acetaminophen) 71 (7%)
Table 6 Pain management during the 3 weeks following baseline assessment
Worst pain reported at baseline assessment (number of patients (percentage by column))
Not at all A little Quite a bit Very much Total
Type of analgesic assumed
No analgesics 254 (94) 344 (79) 130 (53) 37 (50) 765 (75)
WHO 1 15 (6) 73 (17) 77 (31) 19 (26) 184 (18)
WHO 2 — 12 (3) 18 (7) 9 (12) 39 (4)
WHO 3 — 4 (1) 20 (8) 9 (12) 33 (3)
Values in bold indicate inadequate pain management. Pain management is considered adequate with a Pain Management Index X0 (Cleeland et al, 1994).
Table 7 Relationship between adequacy of pain management during the
first 3 weeks and main baseline characteristics (n¼752 patients reporting
pain)
Number of patients (%)
Adequate pain
management
Inadequate pain
management P
Clinical trial 0.005
a
ELVIS 31 (28) 78 (72)
MILES 69 (18) 321 (82)
GEMVIN 36 (14) 217 (86)
Age 0.02
a
o70 years 35 (14) 222 (86)
X70 years 101 (20) 394 (80)
Gender 0.45
b
Male 116 (19) 508 (81)
Female 20 (16) 108 (84)
Performance status 0.26
b
0–1 103 (17) 501 (83)
2 33 (22) 115 (78)
Stage 0.09
b
IIIB 29 (15) 170 (85)
IV 107 (19) 446 (81)
Bone metastases o0.001
b
Absent 79 (14) 468 (86)
Present 57 (28) 148 (72)
aw
2 test.
bMantel–Haenszel test.
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lplanned if reasonable estimates of the major patients’ needs were
available. To the best of our knowledge this is the largest series of
patients with advanced NSCLC in which prevalence of pain at
diagnosis is described. This was possible by pooling the data of
three prospective randomised clinical trials of chemotherapy,
performed by the same cooperative group and coordinated by the
same centre (The ELVIS Group, 1999; Gridelli et al, 2003a,b). All
these trials had very similar selection criteria (except for age that
was discriminant among the studies), study procedures (all the
patients filled-in EORTC questionnaires at baseline) and recom-
mendations about supportive care. The pooled database should be
sufficiently representative of the patients’ population with
advanced NSCLC who are candidate to a systemic treatment with
chemotherapy (Perrone et al, 2002). Because in all of these trials
patients with performance status worse than 2 according to ECOG
(Oken et al, 1982) were excluded, our study does not address
patients with more deteriorated health status, that are probably
those more frequently suffering pain. Such information could only
derive by clinical trials or observational studies specifically
dedicated to terminally ill patients. We found that three-fourths
of patients suffer some degree of pain and in about one-third of
cases this pain does significantly affect daily activities. These
figures are consistent with a smaller series of patients with various
stages of lung cancer (61 cases with localised disease, 91 with
regional, 68 metastatic and 40 with undetermined extension), in
which pain was assessed by a graphic rating scale combining
visual, numerical and descriptive indicators: only 71 out of 256
patients (27.7%) stated they had had no pain in the last week, while
50.7% had suffered moderate to very bad pain (Greenwald et al,
1987). Overall, these data confirm that pain is an issue of great
relevance in the clinical presentation of advanced NSCLC. In the
data we are reporting, the presence of bone metastases seems to be
the key variable associated with occurrence and severity of pain;
indeed, the associations of clinical trial, age and stage with pain
(Table 3) can overall be explained with a slightly higher prevalence
of bone metastases in the GEMVIN study, among patients younger
than 70, and, obviously, in stage IV disease.
An important finding of the present study is that pain has a
strong impact on the QoL of cancer patients. In most functioning
scales, indeed, a clinically relevant change of 6–10 points (Osoba
et al, 1998) was observed with increasing severity of pain.
Although this could be expected, based on other studies with
similar findings in smaller series of patients (Ferrell et al, 1995;
Becker et al, 1997; Wang et al, 1999), it is impressing that the mean
score of self-assessed global QoL for patients without pain is
almost twice as much as for patients with severe pain, and a
progressive and clinically significant (Osoba et al, 1998) decrease
in mean scores is seen for patients with mild and moderate degree
of pain. QoL is currently considered as a primary end point of
treatment and clinical trials planning (American Society of Clinical
Oncology, 1996), and global scores (e.g. that coming from items
29–30 in the EORTC C-30 QLQ) are usually considered as primary
outcome measures. The present data suggest that, in cases where a
high prevalence of pain is expected at baseline, pain could be as
sensitive as primary outcome measure as QoL global score.
Based on such considerations, one could argue that adequate
pain relief could significantly improve overall QoL. Even, the
improvement of QoL provided by adequate analgesic treatment
could probably exceed that attributable to the most effective
anticancer treatments, particularly for a disease, like advanced
NSCLC, not highly sensitive to specific treatments. Unfortunately,
in the present study, we found that more than 80% of patients
suffering some degree of pain received inadequate analgesic
medications, based on WHO ladder strategy for pain management
and the definition of adequacy proposed by Cleeland et al (1994)
with the Pain Management Index. This Index is obviously a
simplification, because it does not take into account the dose but
only the type of analgesic drugs, and it does not consider the
assumption of the so-called ‘adjuvant’ analgesics (corticosteroids,
antidepressants, anticonvulsants) that might play an important
role in cancer pain management. However, the same Index has
been repeatedly used when similar surveys have been realized in
different countries (Cleeland et al, 1994, 1997; Larue et al, 1995;
Wang et al, 1999; Beck and Falkson, 2001; Yun et al, 2003). We
found that, at multivariate analysis, pain treatment adequacy
significantly improves in presence of bone metastases, showing
that the knowledge of bone metastases stimulates a proper
consideration of pain treatment by physicians. On the other side,
the fact that adequacy of treatment is inversely correlated with
severity of pain suggests that the level of communication between
patients and physicians regarding pain is frequently inadequate.
This suggests that the use of self-filled pain scales could be
effective in clinical practice to draw physicians’attention on pain
treatment also in the subgroup of patients without bone
metastases. Experimental data show that the use of self-filled
QoL questionnaires in clinical practice improves the effectiveness
of patient–physician communication (Detmar et al, 2002; Velikova
et al, 2004).
Several factors can produce undertreatment of pain. On the
patient’s side, reluctance to report pain (e.g. because of concerns
about distracting physicians from treatment of underlying disease
or fear that pain means worse disease) has been considered
(Cleary, 2000). Furthermore, patients often refuse treatment with
opioid drugs for unjustified fear of addiction. On the physician’s
side, in addition to failures in pain assessment (Von Roenn et al,
1993), inadequate pain management can occur. This might either
lie on cultural pitfalls or concerns regarding the use of analgesic,
for example, possible side effects, risk of patients addiction and
problems due to strict regulations for the use of controlled
substances (morphine and other strong opioids). The latter issue
has probably played a pivotal role in many countries, including
Italy. Indeed, the absence of consistent national policies on
palliative care and the legal restrictions on the use and availability
of opioid analgesics has been pointed out by an expert committee
of WHO (World Health Organization, 1996). Considering mor-
phine consumption as a surrogate index of pain management, Italy
was at the lowest levels of consumption in Europe, in a monitoring
action performed by WHO (World Health Organization, 2000).
The data of the present study confirm a trend toward an
inappropriately low use of opioids. However, a new law on the
medical use of analgesics has been approved in Italy in February
2001 (Gazzetta Ufficiale della Repubblica Italiana, 2001), when
virtually all the patients analysed here had already been treated.
This law significantly simplifies the procedures for the prescription
of opioids; the possible increase of opioids consumption could
eventually translate into a more adequate pain management,
although latest reports are not encouraging (Mercadante, 2002).
A final note should be done as for age of patients, because older
age has been indicated as a risk factor for pain undertreatment
(Cleeland et al, 1994; Cleeland, 1998; Bernabei et al, 1998). A
possible explanation is that toxic effects like gastrointestinal
Table 8 Predictors of adequacy of analgesic treatment. Binary logistic
model stratified by clinical trial
Covariate
Odds ratio
a (95%
confidence intervals) P
Gender 0.92 (0.54 – 1.56) 0.75
Performance status 1.35 (0.85 – 2.14) 0.20
Stage 1.05 (0.64 – 1.72) 0.86
Bone metastases 2.70 (1.73 – 4.21) o0.0001
Worst pain reported 0.62 (0.45 – 0.85) 0.003
aA higher odds ratio is associated with a greater likelihood of adequate treatment of
pain.
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opioids can be particularly ill-tolerated in elderly patients. If this
were true, because two of the three clinical trials pooled in this
study were dedicated to patients older than 70, adequacy of pain
treatment could have been underestimated in the present analysis.
Because the trials we analysed were dedicated to different patient
populations selected on the basis of the age limit at 70 years, we
cannot adequately test the age effect on pain treatment in
multivariate analysis stratified by clinical trial. However, within
an unstratified model that could be confounded by trial, we found
that undertreatment was even more frequent in the younger than
in the older patients, thus not confirming conclusions from
previous publications.
In conclusion, some recommendations can be done based on
our data: (i) tools for self-assessment of pain should be used in
clinical practice management of patients with advanced cancer, to
reduce underestimation of the symptom; (ii) pain should be clearly
identified as preminent within more generic QoL definition and
pain control should be directly addressed as a primary goal of
treatment both in clinical practice and in clinical trials; (iii)
training of physicians in the correct management of pain should be
encouraged at all levels, to improve the appropriate use of
analgesic drugs; (iv) great attention has to be paid to analgesic
treatment in protocols of anticancer treatment, to avoid frustrating
possible specific effects because of inadequate supportive care.
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